- Home
- WPP vs LNTH Comparison
WPP vs LNTH Comparison
Compare WPP & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | LNTH |
|---|---|---|
| Founded | 1985 | 1956 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WPP | LNTH |
|---|---|---|
| Price | $22.79 | $70.03 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $78.00 |
| AVG Volume (30 Days) | 518.8K | ★ 1.1M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | ★ 86.47 | N/A |
| EPS | 0.47 | ★ 2.39 |
| Revenue | ★ $19,423,208,660.00 | $1,525,933,000.00 |
| Revenue This Year | N/A | $0.01 |
| Revenue Next Year | N/A | $0.52 |
| P/E Ratio | ★ $9.69 | $29.12 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $17.47 | $47.25 |
| 52 Week High | $49.54 | $111.29 |
Technical Indicators
Market Signals| Indicator | WPP | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 71.89 |
| Support Level | $22.32 | $66.36 |
| Resistance Level | $23.92 | $67.45 |
| Average True Range (ATR) | 0.51 | 1.67 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 46.76 | 94.84 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.